Jim Chauvapun has been promoted from Manager to Principal in the Healthcare and Life Sciences practice in Boston.  Over the past four years with ADL, Jim has established a proven track record of successfully assisting clients across the pharmaceutical, biotechnology, and medical device industries.  In this new role, he will focus on developing corporate strategies, managing technology and innovation, enhancing organizational performance, and evaluating growth opportunities to maximize the value of commercial activities and R&D investments within the biopharmaceutical and medical technology arenas. 

Simon Flax served as a Manager in the Strategy & Organization Practice in New York City, working with a wide range of corporate and private equity clients to develop growth strategies and evaluate acquisition opportunities.  He also advised clients on topics of sales and operational effectiveness.  Before joining ADL, Simon worked at several consulting firms including Droege & Comp., Booz Allen Hamilton, and Accenture.  In this new position, he will focus on serving his Private Equity clients and be responsible for growing the practice.

Jennifer Kim joined ADL over two years ago as a Manager in the Strategy & Organization Practice in New York City.  Throughout her consulting career, she has successfully directed the development and implementation of value enhancement initiatives for several private equity and corporate clients, particularly in sales force effectiveness and organizational redesign for niche manufacturing companies. Prior to joining ADL, Jennifer held consulting positions at Booz Allen Hamilton and Droege & Comp.  In this new position, she will contribute to the growth and management of ADL’s Private Equity practice through client relationship development, thought leadership, and project management.

Dr. Daniel Schellenberg was previously a Manager of ADL’s Private Equity Practice in New York City, specializing in project work for primarily mid-size private equity funds.  He successfully led numerous value-generation projects and market due diligence assignments within industries such as automotive, energy & renewable energy, boating, and others.  He also developed strong capabilities for market entry strategies in the US, Europe, and Eastern Asia.  Prior to his work at ADL, he led teams for top management consulting firms including Roland Berger Strategy Consultants and Droege & Comp.  Daniel will continue to help private equity clients to strengthen their portfolios, which will include working with their existing portfolio companies on topics such as revenue protection, operational improvement, and cost efficiency initiatives.  He will also focus on improving the portfolio structure of his PE clients by giving advice on adding or eliminating companies from their respective portfolios.

Jean-Paul Valensi was previously a Manager of ADL’s Healthcare and Life Sciences Practice in Boston, focused on project work in Strategy and Organization.  Mr. Valensi specializes in technology identification and evaluation.  He has successfully led several commercial market assessment, franchise strategy, and technology assessment projects for biotechnology, medical device, pharmaceutical, and consumer product companies.  Prior to his work at ADL, he led teams for ISO Healthcare Consulting (now part of Monitor Group).  Jean-Paul will continue to help Healthcare and Life Science Businesses identify new products and technologies and manage their overall business portfolios. 

In their roles as Principals, all will be responsible for contributing to the impressive growth story of Arthur D. Little, Inc. in the US, both in terms of generating new business opportunities as well as training, mentoring, and hiring the next generation of consultants. According to Markus Lahrkamp, President of Arthur D. Little North America, “Please join me in congratulating these individuals on their promotion and wishing them continued success at our company.”